Idelalisib (CAL-101, GS-1101)

For research use only. Not for use in humans.

製品コードS2226

CAS No. 870281-82-6

Idelalisib (CAL-101, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR. Idelalisib also stimulates autophagy.

サイズ

価格(税別)

10mM (1mL in DMSO)	JPY 27800
10mg	JPY 21900
50mg	JPY 80000
200mg	JPY 212800

最寄りの販売代理店を探す

東京
北海道
東北
北関東
南関東
東海
北信越
近畿
中国
四国
九州

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください：[email protected]

バルク問合せ

代表番号: 03-5615-9297|電子メール：[email protected]|よく尋ねられる質問

文献中Selleckの製品使用例(205)

製品安全説明書

PI3K阻害剤の選択性比較

生物活性

製品説明

ターゲット

p110δ ^[1] (Cell-free assay)	p110γ ^[1] (Cell-free assay)
2.5 nM	89 nM

体外試験

CAL-101 is not sensitive to other PI3K class I subunits including p110α, p110β, and p110γ. CAL-101 specifically blocks FcϵR1 p110δ-mediated CD63 expression with an EC50 of 8 nM in primary basophil. CAL-101 exhibits greater activity in B-cell acute lymphoblastic leukemia (B-ALL) and chronic lymphocytic leukemia (CLL) cells compared with acute myeloid leukemia (AML) and myeloproliferative neoplasm (MPN) cells. CAL-101 produces the reduction in pAktS473, pAktT308, and the downstream target S6 in SU-DHL-5, KARPAS-422 and CCRF-SB cells with EC50 of 0.1 to 1.0 μM. ^[1] CAL-101 induces selective cytotoxicity in CLL cells independent of IgVH mutational status or interphase cytogenetics, primarily through a caspase-dependent mechanism. CAL-101 induces cytotoxicity preferentially to CLL cells compared with normal B cells, without producing cytotoxicity in other hematopoietic cells, compared to LY294002. CAL-101 lacks direct cytotoxic potential to T cells and nature killer (NK) cells. CAL-101 can inhibit production of inflammatory cytokines, such as IL-6, IL-10, TNF-α, and IFN-γ, and activation-induced cytokines, such as CD40L. CAL-101 also antagonizes CD40L-mediated CLL cell survival. ^[2] CAL-101 induces an accumulation of cells in G1 and a decrease in the S-phase population in L1236 and L591 cells, which indicates CAL-101 as a novel strategy for the treatment of hodgkin lymphoma (HL). ^[3]

細胞データ

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
MEC1	NGDqdldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MYPEUXNQ	NHO3d41KSzVyPUKwMlQh\|ryP	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl7OUO1Nkc,OjV7OUmzOVI9N2F-
CLL PBMCs	M1LrNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M1HSbWROW09?	M1fuSGlEPTB;Mj65JI5O	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTlzN{K2O{c,OjV7MUeyOlc9N2F-
U266	NUe4TpFOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYC0NEDPxE1?	NF;kfnk1QCCq		MnLGO\|kvPSViaX7obYJqfGmxbjDyZZRm	NFGxZXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUOzPVM{Oid-MkWzN\|k{OzJ:L3G+
K562	MkL0SpVv[3Srb36gRZN{[Xl?	M176Z\|Eh\|ryP	M2DaPVMhcA>?		NH71b4pKdmirYnn0bY9vKG:oIFHreEBxcG:\|cHjvdplt[XSrb36=	NWDiZ3FDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNVQ4PzVpPkK1NFE1Pzd3PD;hQi=>
K562	NVfMV5pHTnWwY4Tpc44hSXO\|YYm=	MkHsNUDPxE1?	MWGzJIg>		MWfJcohq[mm2aX;uJI9nKFB5MGO2T{BxcG:\|cHjvdplt[XSrb36=	Mn36QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyMUS3O\|UoRjJ3MEG0O\|c2RC:jPh?=
K562	M1TFTWZ2dmO2aX;uJGF{e2G7	NX;6SYFbOSEQvF2=	NVXt[5JMOyCq		MVzJcohq[mm2aX;uJI9nKEeVS{OgdIhwe3Cqb4L5cIF1cW:w	Mnn5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyMUS3O\|UoRjJ3MEG0O\|c2RC:jPh?=
K562	MljOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUixJO69VQ>?	M1jaNlczKGh?		NYOxcFc2UW6qaXLpeIlwdiCxZjDwdo9tcW[ncnH0bY9v	NF2zdYs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCxOFc4PSd-MkWwNVQ4PzV:L3G+
Primary AML cell	M2qzc2Z2dmO2aX;uJGF{e2G7	MnrZNUDPxE1?	NUDufXVoOyCq		MXPJcohq[mm2aX;uJI9nKEGtdDDwbI9{eGixconsZZRqd25?	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTBzNEe3OUc,OjVyMUS3O\|U9N2F-
Primary AML cell	MWHGeY5kfGmxbjDBd5NigQ>?	M1vnTVEh\|ryP	Mke1N{Bp		M{HqfmlvcGmkaYTpc44hd2ZiUEewV\|ZMKHCqb4PwbI9zgWyjdHnvci=>	M1nHRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEG0O\|c2Lz5{NUCxOFc4PTxxYU6=
Primary AML cell	NIT3NW9HfW6ldHnvckBCe3OjeR?=	M4D4bFEh\|ryP	NVz4UZFWOyCq		MYXJcohq[mm2aX;uJI9nKEeVS{OgdIhwe3Cqb4L5cIF1cW:w	NWDu[GdVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNVQ4PzVpPkK1NFE1Pzd3PD;hQi=>
Primary AML cell	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHXG[W4yKM7:TR?=	M1:5c\|MhcA>?		M37FZnN2eHC{ZYPzbY9vKG:oIILSUmEhe3mwdHjld4l{	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTBzNEe3OUc,OjVyMUS3O\|U9N2F-
Microglia	MlPUSpVv[3Srb36gRZN{[Xl?	MkL0OUDPxE1?	MmHSNVAhcA>?	M1;YOGROW09?	MnrwSIVkemWjc3Wgc4YhXE6IYTDz[YNz\XSrb36g[pJwdSCOUGOtd5RqdXWuYYTl[EAheDFzMN80SFkyOEFxREmxNGEhdWmlcn;ncIli	MnrhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4MkW2PFQoRjJ2NkK1Olg1RC:jPh?=
Primary CLL cell	NIXQPVBHfW6ldHnvckBCe3OjeR?=	M3mydVEh\|ryP	NYDyO2Y3OTVibXnu	NXexZmxETE2VTx?=	NIHKZ4RDdG:la4OgRmNTNWmwZIXj[YQhVEOSMTDz[ZJqdmVvNTDhZ5RqfmG2aX;u	M2jYSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEC5NlM{Lz5{NECwPVI{OzxxYU6=
JEKO-1	NGHxToJHfW6ldHnvckBCe3OjeR?=	M3z0T\|Eh\|ryP	Mke4O\|IhcA>?		MYLJcohq[mm2aX;uJI9nKEGtdDDwbI9{eGixconsZZRqd25iaX6gTYdONXO2aX31cIF1\WRiSlXLU{0y	M4H5c\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{SxOVQyLz5{M{O0NVU1OTxxYU6=
Granta-519	NWf3V41mTnWwY4Tpc44hSXO\|YYm=	MmCxNUDPxE1?	MkL5NkBp		MXfJcohq[mm2aX;uJI9nKEGtdDj0N\|A5MSCyaH;zdIhwenmuYYTpc44>	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN2MUW0NUc,OjN\|NEG1OFE9N2F-
Granta-519	MXPGeY5kfGmxbjDBd5NigQ>?	NW[1TIZ{OSEQvF2=	NFewTXAzKGh?		NX3kSIxnUW6qaXLpeIlwdiCxZjDBb5QpezR5MzmgdIhwe3Cqb4L5cIF1cW:w	MnjzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|NEG1OFEoRjJ\|M{SxOVQyRC:jPh?=
JEKO-1	NXe2RYlMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MknkNVAh\|ryP	NFTXS\|c4OiCq		M2TlW2lvcGmkaYTpc44hd2ZicILvcIln\XKjdHnvckB{dGmpaITsfS=>	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN2MUW0NUc,OjN\|NEG1OFE9N2F-
JEKO-1	NYHMeY9XT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUTtOHFWPSEQvF2=	NFnVO\|I4OiCq		NXXmRppI\G:nczDuc5QhcW6mdXPlJINmdGxiY4njcIUh[XK{ZYP0JI9zKGGyb4D0c5Nqew>?	NGPhZWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[3OlIzOCd-MkO2O\|YzOjB:L3G+
MAVER-1	Mn\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml7wOUDPxE1?	MUK3NkBp		MWTkc4V{KG6xdDDpcoR2[2ViY3XscEBkgWOuZTDhdpJme3Rib4KgZZBweHSxc3nz	MoPiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4N{[yNlAoRjJ\|Nke2NlIxRC:jPh?=
MINO	NUTL[odKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHTEZWY2KM7:TR?=	M3XrNlczKGh?		MX7kc4V{KG6xdDDpcoR2[2ViY3XscEBkgWOuZTDhdpJme3Rib4KgZZBweHSxc3nz	NG\pOlE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[3OlIzOCd-MkO2O\|YzOjB:L3G+
SP53	NGLvUGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUiwMlEh\|ryP	NEPMSHk4OiCq		M2\3TYRw\XNibn;0JIlv\HWlZTDj[YxtKGO7Y3zlJIFzemW\|dDDvdkBieG:ydH;zbZM>	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ5NkKyNEc,OjN4N{[yNlA9N2F-
HH	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHnBN4cyOCEQvF2=	NYfERoxIPzJiaB?=	Mln6SG1UVw>?	M4S5Zmlv\HWldHnvckBw\iCjcH;weI9{cXNic3zp[4h1dHl?	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjhyMUm1PUc,OjJ6MEG5OVk9N2F-
Myla	MknBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVryV3h5OTBizszN	NXnaS2lnPzJiaB?=	NYH5SmdPTE2VTx?=	NYLhU5J7\G:nczDuc5QhcW6mdXPlJIFxd3C2b4Ppdy=>	NGHBNVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkiwNVk2QSd-MkK4NFE6PTl:L3G+
SR786	M37RTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3rhN\|ExKM7:TR?=	M1W2S\|czKGh?	M3LzSGROW09?	MUfkc4V{KG6xdDDpcoR2[2ViYYDvdJRwe2m\|	NHm0[nk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkiwNVk2QSd-MkK4NFE6PTl:L3G+
HuT78	NUnzW\|FHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoDYNVAh\|ryP	M3\Zd\|czKGh?	NUDCPHlqTE2VTx?=	MkTp[I9meyCwb4SgbY5lfWOnIHHwc5B1d3Orcx?=	NUG2Um1sRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4NFE6PTlpPkKyPFAyQTV7PD;hQi=>
MJ	MlrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{HPelExKM7:TR?=	M{DHbVczKGh?	MknaSG1UVw>?	MlLM[I9meyCwb4SgbY5lfWOnIHHwc5B1d3Orcx?=	NYfz[4FWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4NFE6PTlpPkKyPFAyQTV7PD;hQi=>
DERL7	MnfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUjPN4d1OTBizszN	M{DZXFczKGh?	MXzEUXNQ	NUHxXIFn\G:nczDuc5QhcW6mdXPlJIFxd3C2b4Ppdy=>	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjhyMUm1PUc,OjJ6MEG5OVk9N2F-
L1236	MUnGeY5kfGmxbjDBd5NigQ>?	NHjEcGYyOCEQvF2=	MUiyJIg>		MlGxTY5pcWKrdHnvckBw\iCDa4SgdIhwe3Cqb4L5cIF1cW:w	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJzMEi3O{c,OjJ{MUC4O\|c9N2F-
L428	MnnHSpVv[3Srb36gRZN{[Xl?	M1XKO\|ExKM7:TR?=	NYrk[IVDOiCq		NYO4bVFOUW6qaXLpeIlwdiCxZjDBb5QheGixc4Doc5J6dGG2aX;u	NED3VpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkKxNFg4Pyd-MkKyNVA5Pzd:L3G+
L591	NILLfoFHfW6ldHnvckBCe3OjeR?=	M1jhdlExKM7:TR?=	MVWyJIg>		Ml23TY5pcWKrdHnvckBw\iCDa4SgdIhwe3Cqb4L5cIF1cW:w	NXfLVYN2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyNVA5PzdpPkKyNlExQDd5PD;hQi=>
KMH-2	MonDSpVv[3Srb36gRZN{[Xl?	MUGxNEDPxE1?	M1uxd\|IhcA>?		M3\rWGlvcGmkaYTpc44hd2ZiQXv0JJBpd3OyaH;yfYxifGmxbh?=	NXjLUVg2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyNVA5PzdpPkKyNlExQDd5PD;hQi=>
L1236	NGTXT2tHfW6ldHnvckBCe3OjeR?=	M1HnblUh\|ryP	MmHUNlQhcA>?		NFLRWVBDdG:la4Ogd4VkemW2aX;uJI9nKHSqZTDDR2w2	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJzMEi3O{c,OjJ{MUC4O\|c9N2F-
L591	MlPnSpVv[3Srb36gRZN{[Xl?	MmLWOUDPxE1?	NF;pR5EzPCCq		M2DlUGJtd2OtczDz[YNz\XSrb36gc4YhfGinIFPDUFU>	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJzMEi3O{c,OjJ{MUC4O\|c9N2F-
L1236	NUn1ZZI5SXCxcITvd4l{KEG\|c3H5	Mm\pOUDPxE1?	NEnQVmMzPCCq		MWjJcoR2[3Srb36gc4Yh[XCxcITvd4l{	NELzTXU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkKxNFg4Pyd-MkKyNVA5Pzd:L3G+
L591	NUHaSpE1SXCxcITvd4l{KEG\|c3H5	NGDSZno2KM7:TR?=	M{\GNFI1KGh?		NVnJO4JVUW6mdXP0bY9vKG:oIHHwc5B1d3Orcx?=	M2DPXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MkGwPFc4Lz5{MkKxNFg4PzxxYU6=
U-87MG	M4P3RWZ2dmO2aX;uJGF{e2G7	Ml\oNVAxKG6P	M37mdVI1KGh?	M1jIWGROW09?	NUjUR2VQUW6qaXLpeIlwdiCxZjCgZ4VtdCCvaXfyZZRqd25?	M4DVfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MEe5OlA6Lz5{MkC3PVYxQTxxYU6=
SW1783	M1OzfWZ2dmO2aX;uJGF{e2G7	NFXWNpEyODBibl2=	NWTEVZhwOjRiaB?=	MWDEUXNQ	MUfJcohq[mm2aX;uJI9nKCClZXzsJI1q\3KjdHnvci=>	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjB5OU[wPUc,OjJyN{m2NFk9N2F-
U-87MG	NX\XU49LTnWwY4Tpc44hSXO\|YYm=	NV3tW2RHPSEQvF2=	M2nMSVI1KGh?	NIXPVopFVVOR	Mn63TY5pcWKrdHnvckBw\iCDa4SgdIhwe3Cqb4L5cIF1cW:wIIP1ZpN1[W62aXHscJk>	M1jBfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MEe5OlA6Lz5{MkC3PVYxQTxxYU6=
SW1783	M1XXZ2Z2dmO2aX;uJGF{e2G7	MYm1JO69VQ>?	MnX4NlQhcA>?	Mkn2SG1UVw>?	MUDJcohq[mm2aX;uJI9nKEGtdDDwbI9{eGixconsZZRqd25ic4Xid5RidnSrYXzsfS=>	NIXNO\|c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkC3PVYxQSd-MkKwO\|k3ODl:L3G+
U-373MG	NHjyOpRHfW6ldHnvckBCe3OjeR?=	NX\uOIU4PSEQvF2=	MkPRNlQhcA>?	M{HnTGROW09?	MXrJcohq[mm2aX;uJI9nKEGtdDDwbI9{eGixconsZZRqd25ic4Xid5RidnSrYXzsfS=>	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjB5OU[wPUc,OjJyN{m2NFk9N2F-
SK-MG3	MULGeY5kfGmxbjDBd5NigQ>?	NVTDXXF3PSEQvF2=	NELzUmYzPCCq	MU\EUXNQ	MUTJcohq[mm2aX;uJI9nKEGtdDDwbI9{eGixconsZZRqd25ic4Xid5RidnSrYXzsfS=>	NUXLOFJrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKwO\|k3ODlpPkKyNFc6PjB7PD;hQi=>
SU-DHL-5	MljCSpVv[3Srb36gRZN{[Xl?	NFv6NWQyKM7:TR?=	NELYcpAzPCCq	MYPEUXNQ	NFPiTYVKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|	MnrBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB7NUm2NFYoRjJyOUW5OlA3RC:jPh?=
WSU-NHL	NEHCd2lHfW6ldHnvckBCe3OjeR?=	NHPMcmUyKM7:TR?=	MojiNlQhcA>?	NYP0XFRGTE2VTx?=	MVzJcoR2[3Srb36gc4Yh[XCxcITvd4l{	NYWx[GRlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC5OVk3ODZpPkKwPVU6PjB4PD;hQi=>
CCRF-SB	NUfPVVFSTnWwY4Tpc44hSXO\|YYm=	Ml7SNUDPxE1?	MUmyOEBp	NWHSTm9wTE2VTx?=	MV;JcoR2[3Srb36gc4Yh[XCxcITvd4l{	M1XQblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyOUW5OlA3Lz5{MEm1PVYxPjxxYU6=
INA-6	MYXGeY5kfGmxbjDBd5NigQ>?	NYrLdXJMPSEQvF2=	NYDBXopGPiCq		NUf4elZ1UW6qaXLpeIlwdiCxZjDQTVNMN0GtdDDhcoQhTVKNIIDheIh4[Xl?	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODVyNUG1PEc,OjB3MEWxOVg9N2F-
LB	NFjGd4RHfW6ldHnvckBCe3OjeR?=	MUC1JO69VQ>?	MlSxOkBp		MX\Jcohq[mm2aX;uJI9nKFCLNFuvRYt1KGGwZDDFVmsheGG2aIfhfS=>	NGTZUXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEWwOVE2QCd-MkC1NFUyPTh:L3G+
B-cells	NXPTfoVpTnWwY4Tpc44h[XO\|YYm=				MUTJcohq[mm2aX;uJI9nKFCLM1vk[Yx1[SCrbjDCMYNmdGy\|IHL5JJBzd2yrZnXyZZRqd25iYYPzZZktKEmFNUCgQUAxNjByNkGg{txONg>?	NYLNZ5NpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK5NlQ3QDhpPkKyPVI1Pjh6PD;hQi=>
MOLM14	NUDqVXZOSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M4DXflMh\GG7cx?=		MXfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2RTF2xOEBk\WyuczDh[pRmeiB\|IHThfZMh[nliQ3XscHRqfGW{LVfsc{Bie3OjeTygTWM2OCB;IEOuOkDPxE1w	M{DhXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5N{e0NVI4Lz5{N{e3OFEzPzxxYU6=
MV4-11	NYrLOFFxSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M134U\|Mh\GG7cx?=		NU\E[ZhySW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNWlQuOTFiY3XscJMh[W[2ZYKgN{Bl[Xm\|IHL5JGNmdGyWaYTldk1IdG9iYYPzZZktKEmFNUCgQUA3NjNizszNMi=>	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzd5NEGyO{c,Ojd5N{SxNlc9N2F-
Jurkat	MXjBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NU\CNYkyOyCmYYnz		NHvEPYRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFr1dotifCClZXzsd{Bi\nSncjCzJIRigXNiYomgR4VtdFSrdHXyMWdtdyCjc4PhfUwhUUN3MDC9JFcvQSEQvF2u	NYjQW3hwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke3O\|QyOjdpPkK3O\|c1OTJ5PD;hQi=>
Loucy	MnfWRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MonCN{Bl[Xm\|		MlS0RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCOb4XjfUBk\WyuczDh[pRmeiB\|IHThfZMh[nliQ3XscHRqfGW{LVfsc{Bie3OjeTygTWM2OCB;IEiuOEDPxE1w	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzd5NEGyO{c,Ojd5N{SxNlc9N2F-
MOLT4	NIX0dldCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		Mni5N{Bl[Xm\|		NGTsNZBCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3PUHQ1KGOnbHzzJIFnfGW{IEOg[IF6eyCkeTDD[YxtXGm2ZYKtS4xwKGG\|c3H5MEBKSzVyIE2gNVAvPiEQvF2u	M3joRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5N{e0NVI4Lz5{N{e3OFEzPzxxYU6=
insect cells	NYDp[opGTnWwY4Tpc44h[XO\|YYm=				Ml:zTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDoeY1idiCodXzsJIxmdme2aDDIbZMufGGpZ3XkJHBKO0upYX3tZUBmgHC{ZYPz[YQhcW5iaX7z[YN1KGOnbHzzMEBKSzVyIE2gNE4xQDlizszNMi=>	NXLUfWxSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke4OFY1PTFpPkK3PFQ3PDVzPD;hQi=>
SUDHL6	Mme3RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NIrRUoM4OiCqcoO=		Mnv3RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCVVVTIUFYh[2WubIOgcYVie3W{ZXSgZYZ1\XJiN{KgbJJ{KGK7IHHsZY1ieiCkbIXlJIF{e2G7LDDJR\|UxKD1iMD6xNVc3KM7:TT6=	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzh2NkS1NUc,Ojd6NE[0OVE9N2F-
insect cells	M4nIdWZ2dmO2aX;uJIF{e2G7				M3q1[mlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5iZoXscEBt\W6pdHigTIl{NXSjZ3fl[EBRUTONYnX0ZUBmgHC{ZYPz[YQhcW5iaX7z[YN1KGOnbHzzMEBKSzVyIE2gNE42PjVizszNMi=>	M3ewe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OES2OFUyLz5{N{i0OlQ2OTxxYU6=
SU-DHL4	NHrt[W5CdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NUC3TppGPzJiaILz		M2fNb2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU2WtSGhNPCClZXzsd{Bu\WG\|dYLl[EBi\nSncjC3NkBpenNiYomgZYxidWG{IHLseYUh[XO\|YYmsJGlEPTBiPTCxMlYh\|ryPLh?=	NV3hdY4{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke4OFY1PTFpPkK3PFQ3PDVzPD;hQi=>
Pfeiffer	MUXBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NFOwSGE4OiCqcoO=		M1m0TWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUH\lbYZn\XJiY3XscJMhdWWjc4Xy[YQh[W[2ZYKgO\|IhcHK\|IHL5JIFt[W2jcjDicJVmKGG\|c3H5MEBKSzVyIE2gOk45KM7:TT6=	M1PMb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OES2OFUyLz5{N{i0OlQ2OTxxYU6=
KARPAS422	MWXBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NFjyPVM4OiCqcoO=		NGj2bGpCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFvBVnBCWzR{MjDj[YxteyCvZXHzeZJm\CCjZoTldkA4OiCqcoOgZpkh[WyjbXHyJIJtfWViYYPzZZktKEmFNUCgQUA5NjFizszNMi=>	NFGyTnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{i0OlQ2OSd-Mke4OFY1PTF:L3G+
Sf21	MlS2SpVv[3Srb36gZZN{[Xl?		NI\Od44{OCCvaX7z		NHjSU4RKdmirYnn0bY9vKG:oIF6teIVzdWmwYXygTIl{Pi22YXfn[YQhemWlb33ibY5idnRiZoXscE1t\W6pdHigbJVu[W5iUFmzT{BxOTFyYnX0ZU92dnSjZ3fl[EBz\WOxbXLpcoFvfCCodXzsJIxmdme2aDDoeY1idiCyOEXhcJBp[SCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhW2Z{MTDpcpNm[3RiY3XscJMhfXOrbnegVGlROi:DVGCgZZMhe3Wkc4TyZZRmKGGodHXyJFMxKG2rboOgZpkhXFJvRmLFWEBie3OjeTygTWM2OCB;IEOuO{DPxE1w	MnfIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhzME[5PVEoRjJ6MUC2PVkyRC:jPh?=
Sf21	NGq5O2pHfW6ldHnvckBie3OjeR?=		NF\pd20{OCCvaX7z		NU\qRWJDUW6qaXLpeIlwdiCxZjDOMZRmem2rbnHsJGhqezZvdHHn[4VlKHKnY3;tZolv[W62IH\1cIwudGWwZ4ToJIh2dWGwIGDJN2sheDFzMHLleIEwfW62YXfn[YQhemWlb33ibY5idnRiZoXscEBt\W6pdHigbJVu[W5icEi1ZYxxcGFiZYjwdoV{e2WmIHnuJIJi[3Wub4\pdpV{KGmwZnXjeIVlKFOoMkGgbY5{\WO2IHPlcIx{KHW\|aX7nJHBKWDJxQWTQJIF{KHO3YoP0doF1\SCjZoTldkA{OCCvaX7zJIJ6KFSULV\SSXQh[XO\|YYmsJGlEPTBiPTCzMlch\|ryPLh?=	MlW0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhzME[5PVEoRjJ6MUC2PVkyRC:jPh?=
RPMI8266	MlHJRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MnL0O\|IhcHK\|		M1mwW2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUmDNTVgzPjZiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFAvODB3NEmg{txONg>?	NIDnR3o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEOyOVYxOSd-MkizNlU3ODF:L3G+
Raji	NU\FfG1QSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M4fCVlczKGi{cx?=		MkPDRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCUYXrpJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkCwPVk2KM7:TT6=	MoLFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh\|MkW2NFEoRjJ6M{K1OlAyRC:jPh?=
KARPAS422	MmnUS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				MlLwS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gT2FTWEGVNEKyJINmdGy\|IHL5JGNEUzhiYYPzZZktKEeLNUCgQUAxNjZ6IN88UU4>	NXXJfGdrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4N\|U5ODVpPkK4PFM2QDB3PD;hQi=>
Pfeiffer	Mn7YS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				NWOwSGQ1T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hWG[naX\m[ZIh[2WubIOgZpkhS0ONODDhd5NigSxiR1m1NEA:KDBwN{Sg{txONg>?	M3PST\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEO1PFA2Lz5{OEizOVgxPTxxYU6=
Saos-2	NVTYcVdDeUiWUzDhd5NigQ>?				MYXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW2Gxcz2yJINmdGy\|	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-SH	MmS5dWhVWyCjc4PhfS=>				MYXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3TTEBk\Wyucx?=	M{HNdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
MG 63 (6-TG R)	NI\EbI5yUFSVIHHzd4F6				NGrZSHVyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTVegOlMhMDZvVFegVkkh[2WubIO=	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
NB1643	NUDKVpE5eUiWUzDhd5NigQ>?				NYDoenNIeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF7CNVY1OyClZXzsdy=>	M1G2dlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
OHS-50	MYXxTHRUKGG\|c3H5				M1;RZ5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCRSGOtOVAh[2WubIO=	NVz4fGV4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh41	Mm\2dWhVWyCjc4PhfS=>				NFWwUnlyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUni0NUBk\Wyucx?=	NV7L[5pORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-MC	MULxTHRUKGG\|c3H5				MlzudWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tUWMh[2WubIO=	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
NB-EBc1	MXnxTHRUKGG\|c3H5				M{fNPZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQj3FRoMyKGOnbHzz	NX3FZlFnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
LAN-5	M4DCSpFJXFNiYYPzZZk>				NH\oSVNyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTFHOMVUh[2WubIO=	NGfRZVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SUDHL6	NUPRSnZZSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M3TWSFczKGi{cx?=		MmfZRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCVVVTIUFYh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPDT\|gh[XO\|YYmsJGlEPTBiPTCwMlY2KM7:TT6=	M324ZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUO0PVM3Lz5{OUWzOFk{PjxxYU6=
RPMI8226	MVnBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NUHYe\|l3PzJiaILz		NUPzWnpYSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDSVG1KQDJ{NjDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hPS52OTFOwG0v	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTV\|NEmzOkc,Ojl3M{S5N\|Y9N2F-
Raji	MnPCRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MnXZO\|IhcHK\|		Mmj0RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCUYXrpJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSB7Lkm1JO69VS5?	NXnQbZNpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1N\|Q6OzZpPkK5OVM1QTN4PD;hQi=>
SU-DHL6	NWnQVoVCT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=				NUXjTFFKT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hW1VvRFjMOkBk\WyuczDifUBE\WyuVHn0[ZIuT2yxIHHzd4F6NCCJSUWwJF0hOC5yNEKg{txONg>?	NWryfm9qRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm2NFE6QTFpPkK5OlAyQTlzPD;hQi=>
MOLM13	MVnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NUG1[mlwPzJiaILz		MXPHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDNU2xOOTNiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JGNmdGyWaYTldk1IdG9ibIXtbY5me2OnboSgZZN{[XluIFfJOVAhRSBzLkeg{txONg>?	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB3M{eyNUc,OzByNUO3NlE9N2F-
MOLM14	MnfLS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MnK3O\|IhcHK\|		NEixe5NIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBOV0yPMUSgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRmei2JbH:gcJVucW6nc3PlcpQh[XO\|YYmsJGdKPTBiPTC2MlQh\|ryPLh?=	NIXINGc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEC1N\|czOSd-M{CwOVM4OjF:L3G+
MOLM14	NV7VTZhvSW62aYT1cY9zKGG\|c3H5	M4ns[FExOCCvZz;r[y=>	NYq3VGc4OTRiZHH5dy=>		MmfKRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTV;MUVE1KGOnbHzzJJhmdm:pcnHmeIVlKGmwIH71M452KG2xdYPlJIF{e2W\|c3XkJIF{KHS3bX;yJIdzd3e2aDDpcohq[mm2aX;uJIF1KDFyMDDt[{9s\yxicH:gZYRucW6rc4TldoVlKGSjaXz5JJZq[SCpYY\h[4Uh\G:\|ZXSg[o9zKDF2IHThfZMh[W6mIH3lZZN2emWmIHThbYx6KGS3cnnu[{Bkd22yb4Xu[EBld3OrbnegdoVt[XSrdnWgeI8h[2:wdILvcC=>	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB3M{eyNUc,OzByNUO3NlE9N2F-
MOLM14	NEn6SJNCdnSrdIXtc5Ih[XO\|YYm=	NXKyenBNOTByIH3nM4to	M4fBU\|E1KGSjeYO=		M2jjZ2FvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3PUG0yPCClZXzsd{B5\W6xZ4Lh[pRm\CCrbjDueU9vfSCvb4Xz[UBie3Onc4Pl[EBieyCrbnT1Z5Rqd25ib3[gZZBweHSxc3nzJIF1KDFyMDDt[{9s\yxicH:gZYRucW6rc4TldoVlKGSjaXz5JJZq[SCpYY\h[4Uh\G:\|ZXSg[o9zKDF2IHThfZMh[W6mIH3lZZN2emWmIHThbYx6KGS3cnnu[{Bkd22yb4Xu[EBld3OrbnegZpkhXFWQRVygZoF{\WRiYYPzZZk>	MnP6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByNUO3NlEoRjNyMEWzO\|IyRC:jPh?=
MOLM14	NGXXdotCdnSrdIXtc5Ih[XO\|YYm=	Ml:4NVAxKG2pL3vn	MlnUNVQh\GG7cx?=		M1HmTmFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3PUG0yPCClZXzsd{B5\W6xZ4Lh[pRm\CCrbjDueU9vfSCvb4Xz[UBie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJR2dW:{IIDyc4xq\mW{YYTpc44hOTByIH3nM4toNCCybzDh[I1qdmm\|dHXy[YQh\GGrbImgeoliKGejdnHn[UBld3OnZDDmc5IhOTRiZHH5d{BidmRibXXhd5Vz\WRiZHHpcJkh\HW{aX7nJINwdXCxdX7kJIRwe2mwZzDifUBMcS14NzDsZYJmdGyrbnegZoF{\WRiaX3teY5wcA>?	NY\xe4h3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwOVM4OjFpPkOwNFU{PzJzPD;hQi=>

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ

Methods	Test Index	PMID
Western blot	Akt(T308) / PDK1(S241) / GSK-3β(S9); PubMed: 27342398 Clin Cancer Res JeKo-1, Mino, and Granta 519 cells or cells from four different MCL patients were serum-starved for 1h and then treated with DMSO, or with 0.5, 1, or 3μM for 1h; the cells were then co-cultured with IgM (10ng/μL) for 15min before harvesting. Cell extracts were prepared, and 30μg (cell lines) or 50μg (primary cells) protein was loaded for immunoblot analyses. The effects of idelalisib on Akt (Thr308) and total Akt, PDK1 (Ser241) and total PDK1, GS3K-3β (Ser9) and total GSK-3β protein expression levels were detected in (A) JeKo-1, Mino and Granta 519 cells. p-FoxO3a / FoxO3a; PubMed: 30224718 Cell Death Dis HepG2 cells were treated with 5 μmol/L idelalisib for 24 h. Indicated protein expression was analyzed by western blotting and p-FoxO3a normalized to FoxO3a, p-AKT normalized to AKT. The data represent the mean ± SD of three independent experiments. P < 0.01 (one-way ANOVA with Tukey’s post hoc test). Mcl-1 / Bcl-2 / Bid / Bcl-xl / Noxa / Bak / Bax ; PubMed: 30224718 Cell Death Dis HepG2 cells were treated with 5 μmol/L idelalisib at indicated time points. The expression of indicated Bcl-2 family members was analyzed by western blotting and normalized to β-actin. The data represent the mean ± SD of three independent experiments. P < 0.01 (one-way ANOVA with Tukey’s post hoc test). Cleaved caspase 3 / Cleaved caspase 9; PubMed: 28008149 Oncotarget HepG2 cells were treated with 5μmol/L idelalisib at indicated time point. Cleaved-caspase 3 and 9 were analyzed by western blotting. p-AKT / AKT; PubMed: 28008149 Oncotarget HCT116 cells were treated with 10 μmol/L idelalisib at indicated time point. Total AKT and p-AKT expression was analyzed Western blotting. p-p65; PubMed: 28008149 Oncotarget HCT116 cells were treated with 10 μmol/L idelalisib at indicated time point. p-p65 (S536) and p65 expression was analyzed by Western blotting. Bim / Bcl-xl / Bid / Mcl-1; PubMed: 28008149 Oncotarget HCT116 cells treated with 10 μmol/L idelalisib at indicated time point. The expression of indicated Bcl-2 family members was analyzed by Western blotting. PUMA / p53 ; PubMed: 28008149 Oncotarget Parental and p53-KD HCT116 cells were treated with 10 μmol/L idelalisib for 24 hours. PUMA expression was analyzed by Western blotting.	27342398 30224718 28008149
Growth inhibition assay	Cell viability; PubMed: 30224718 Cell Death Dis The indicated cell lines were treated with increasing concentrations of idelalisib for 72 h. Cell viability was determined by MTS assay. Cell viability; PubMed: 28008149 Oncotarget Indicated cell lines were treated with different concentrations of idelalisib for 72 hours. Cell proliferation was determined by MTS assay. Results were expressed as means ± SD of three independent experiments.	30224718 28008149

お薦めの試験操作（参考用のみ）

キナーゼ試験：^[2]	- 合併 PI3K assay: PI3K assay is preformed on whole-cell lysates from CLL or normal B cells. A PI3K ELISA assay is performed. Briefly, whole-cell extracts are added to a mixture of PI(4,5)P2 substrate and reaction buffer containing adenosine triphosphate (ATP) and allowed to incubate at room temperature. The reaction is stopped by adding PI(3,4,5)P3 detector mixed with EDTA (ethylenediaminetetraacetic acid) and allowed to incubate at room temperature for 1 hour. After this time, the mixture is transferred from each well to a PI3K ELISA plate and allowed to incubate 1 hour. Plates are washed and then incubated with secondary detector for 30 minutes. Plates are washed again, and 3,3′,5,5′-tetramethylbenzidine solution is added for 5 minutes at which time H2SO4 is added to stop all reactions. Plates are read at 450 nm on a Labsystems 96-well plate reader.
細胞試験： ^[2]	- 合併細胞株： CLL B cells or healthy volunteer T cells or NK cells 濃度： 0.01-100 μM 反応時間： 48 hours 実験の流れ： MTT assays are performed to determine cytotoxicity. 1 × 10⁵ cells are incubated with CAL-101. MTT reagent is then added, and plates are incubated for an additional 20 hours before washing with protamine sulfate in phosphate-buffered saline. DMSO is added, and absorbance is measured by spectrophotometry at 540 nm in a Labsystems plate reader. Cell viability is also measured at various time points with the use of annexin/PI flow cytometry. Data are analyzed. At least 104 cells are counted for each sample. Results are expressed as the percentage of total positive cells over untreated control. Experiments examining caspase-dependent apoptosis included the addition of 100 μM Z-VAD. Experiments examining survival signals include the addition of 1 μg/mL CD40L, 800 U/mL IL-4, 50 ng/mL BAFF, 20 ng/mL TNF-α, or coculturing on fibronectin or stromal (HS-5 cell line) coated plates. Stromal coculture is done by plating a 75-cm² flask (80%-100% confluent) per 6-well plate 24 hours before the addition of CLL cells. (参考用のみ)

キナーゼ試験：^[2]

- 合併

PI3K assay:

PI3K assay is preformed on whole-cell lysates from CLL or normal B cells. A PI3K ELISA assay is performed. Briefly, whole-cell extracts are added to a mixture of PI(4,5)P2 substrate and reaction buffer containing adenosine triphosphate (ATP) and allowed to incubate at room temperature. The reaction is stopped by adding PI(3,4,5)P3 detector mixed with EDTA (ethylenediaminetetraacetic acid) and allowed to incubate at room temperature for 1 hour. After this time, the mixture is transferred from each well to a PI3K ELISA plate and allowed to incubate 1 hour. Plates are washed and then incubated with secondary detector for 30 minutes. Plates are washed again, and 3,3′,5,5′-tetramethylbenzidine solution is added for 5 minutes at which time H2SO4 is added to stop all reactions. Plates are read at 450 nm on a Labsystems 96-well plate reader.

細胞試験： ^[2]

- 合併

細胞株： CLL B cells or healthy volunteer T cells or NK cells
濃度： 0.01-100 μM
反応時間： 48 hours
実験の流れ： MTT assays are performed to determine cytotoxicity. 1 × 10⁵ cells are incubated with CAL-101. MTT reagent is then added, and plates are incubated for an additional 20 hours before washing with protamine sulfate in phosphate-buffered saline. DMSO is added, and absorbance is measured by spectrophotometry at 540 nm in a Labsystems plate reader. Cell viability is also measured at various time points with the use of annexin/PI flow cytometry. Data are analyzed. At least 104 cells are counted for each sample. Results are expressed as the percentage of total positive cells over untreated control. Experiments examining caspase-dependent apoptosis included the addition of 100 μM Z-VAD. Experiments examining survival signals include the addition of 1 μg/mL CD40L, 800 U/mL IL-4, 50 ng/mL BAFF, 20 ng/mL TNF-α, or coculturing on fibronectin or stromal (HS-5 cell line) coated plates. Stromal coculture is done by plating a 75-cm² flask (80%-100% confluent) per 6-well plate 24 hours before the addition of CLL cells.
(参考用のみ)

参考

溶解度 (25°C)

体外	DMSO	83 mg/mL (199.79 mM) warming
	Ethanol	23 mg/mL (55.36 mM)
	Water	Insoluble
体内	左から（NMPから）右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ): 2% DMSO+20%PEG 300+ddH2O 混合させたのち直ちに使用することを推奨します。	5mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報 Idelalisib (CAL-101, GS-1101) SDFをダウンロードする

分子量	415.42
化学式	C₂₂H₁₈FN₇O
CAS No.	870281-82-6
Storage	3 years-20°C powder 2 years-80°C in solvent
別名	N/A
Smiles	CCC(C1=NC2=C(C(=CC=C2)F)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5

投与溶媒組成計算器(クリア溶液)

ステップ１：実験データを入力してください。（実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します）

投与量

mg/kg

動物平均体重

投与体積（動物毎）

動物数

匹

ステップ２：投与溶媒の組成を入力してください。（ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください）

% DMSO+ % + % Tween 80+ % ddH₂O

計算リセット

計算結果:

投与溶媒濃度： mg/ml；

DMSOストック溶液調製方法： mg 試薬を μL DMSOに溶解する（濃度 mg/mL，注：濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。）

投与溶媒調製方法：μL DMSOストック溶液に μL PEG300，を加え、完全溶解後μL Tween 80，を加えて完全溶解させた後 μL ddH₂O，を加え完全に溶解させます。

注意：１.ストック溶液に沈殿、混濁などがないことをご確認ください；
２.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

便利ツール

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

質量

濃度

体積

分子量
=

×

×

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとSDS/COA（製品ページで利用可能な）。

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます：

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます：C1V1 = C2V2 ( 入力出力 )

C1

V1

C2

V2
×

=

×

常に貯蔵液を準備するとき、小びんラベルとSDS/COA（オンラインで利用できる）で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

連続希釈剤
初めの濃度：
稀釈倍数：

計算結果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください：

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量	濃度	体積	分子量
=	×	×

臨床試験 (data from https://clinicaltrials.gov, updated on 2021-09-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03582098	Completed	Drug: Idelalisib\|Drug: Rituximab	Chronic Lymphocytic Leukaemia	Gilead Sciences	September 12 2018	--
NCT03151057	Active not recruiting	Drug: Idelalisib 100 MG\|Drug: Placebo Oral Tablet	B Cells-Tumors\|B Cell Chronic Lymphocytic Leukemia\|Follicular Lymphoma\|Mantle Cell Lymphoma\|Large B-Cell Diffuse Lymphoma of Bone (Diagnosis)	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|Gilead Sciences	July 31 2018	Phase 1
NCT03568929	Active not recruiting	Drug: Idelalisib	Follicular Non-Hodgkin''s Lymphoma Refractory	Gilead Sciences	May 25 2018	--

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須
*大学・企業名:
*名前:
*電子メール:
*電話番号:
*内容:

よくある質問（FAQ）

質問1：
What is the recommended dose of CAL-101 and the route of administration for mouse studies?
回答：
According to the following paper, S2226 can be used by I.V. administration at the concentration of 40 mg/kg. https://www.ncbi.nlm.nih.gov/pubmed/24625684

PI3Kシグナル伝達経路

PI3K Inhibitors with Unique Features

Pan PI3K Inhibitor

LY294002 : Pan-PI3Kα/δ/β inhibitor, IC50=0.5 μM/0.57 μM/0.97 μM.
Most Potent PI3K Inhibitor

Duvelisib (IPI-145, INK1197) : PI3K δ, IC50=1 nM.
PI3K Inhibitor in Clinical Trial

Hexestrol : Phase II for Advanced Breast Cancer.
Newest PI3K Inhibitor

GSK2636771 : Potent, orally bioavailable, PI3Kβ-selective inhibitor, sensitive to PTEN null cell lines.

相関PI3K製品

Taselisib (GDC 0032)

Taselisib (GDC 0032, RG7604) is a potent, next-generation β isoform-sparing PI3K inhibitor targeting PI3Kα/δ/γ with K_i of 0.29 nM/0.12 nM/0.97nM, >10 fold selective over PI3Kβ.

Features:A beta isoform-sparing PI3K inhibitor.
Pilaralisib (XL147)

Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.
LY294002

LY294002 (SF 1101, NSC 697286) is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. LY294002 also inhibits CK2 with IC50 of 98 nM. LY294002 is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis.
3-Methyladenine (3-MA)

3-Methyladenine (3-MA, NSC 66389) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. 3-Methyladenine (3-MA) is successfully used to suppress mitophagy. Solutions of 3-MA are best fresh-prepared by heating.
Wortmannin (KY 12420)

Wortmannin (KY 12420, SL-2052, BRN 0067676, NSC 627609) is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Wortmannin blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays. Wortmannin also inhibits PLK1 activity.
Dactolisib (BEZ235)

Dactolisib (BEZ235, NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assays, respectively. Inhibits ATR with IC50 of 21 nM in 3T3^TopBP1-ER cell. Dactolisib induces autophagy and suppresses HIV-1 replication. Phase 2.
Buparlisib (BKM120)

Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Buparlisib induces apoptosis. Phase 2.

研究分野別

製品類型

Idelalisib (CAL-101, GS-1101)

文献中Selleckの製品使用例(205)

製品安全説明書

PI3K阻害剤の選択性比較

生物活性

お薦めの試験操作（参考用のみ）

参考

溶解度 (25°C)

化学情報 Idelalisib (CAL-101, GS-1101) SDFをダウンロードする

投与溶媒組成計算器(クリア溶液)

便利ツール

モル濃度計算器

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

希釈計算器

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

連続希釈計算器方程式

連続希釈剤

計算結果

分子量计算器

総分子量：g/mol

モル濃度計算器

臨床試験 (data from https://clinicaltrials.gov, updated on 2021-09-06)

技術サポート

よくある質問（FAQ）

PI3Kシグナル伝達経路

PI3K Inhibitors with Unique Features

相関PI3K製品